The Pep Edit Newsletter

Cheat sheet

Status: Not FDA-approved Reviewed

ARA-290

Nicknamed the nerve repair peptide. If you found it by searching for nerve pain, here is what the studies actually did and did not show.

The evidence rail

How to read this
  1. Mechanistic: reached
  2. Cell research: reached
  3. Animal research: reached
  4. Human observational: reached
  5. Human clinical trial: reached, limited data
  6. Established clinical use: not reached
Evidence
Small controlled trialsRung 5 of 6, limited data. A designed trial in people with a comparison group. The bar for a real claim.
Status
Not FDA-approvedNot approved for use as a drug. Often sold as a research chemical.

What has it been studied for?

  • Neuropathic pain and inflammation in early human work
  • Innate repair receptor signaling in preclinical models

What we know

  • Small randomized, placebo-controlled trials exist, mostly in small fiber neuropathy. The nickname is more famous than the sample sizes

What we don’t

  • Whether those small trials become a durable, replicated clinical story in larger ones

Bottom line

A nickname is not a proof.

Education only. Not medical advice. Not a protocol.

Keep reading

  • KPV

    A fragment of alpha-MSH studied for inflammation and skin. Small human data.

    Evidence: Small human studies. Reached rung 4 of 6, Human observational.Not FDA-approved
    InflammationGut healthSkin + hair
    Inflammation

  • BPC-157

    Widely discussed for gut and recovery. The animal literature is large. Human clinical evidence is still thin.

    Evidence: Limited human data. Reached rung 4 of 6, Human observational, with limited data.Not FDA-approved
    Gut healthRecoveryInflammation
    Gut / Recovery

New sheets, the day they publish.

One email a week. The study type named, every time.